Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2020

View Archived Issues

CanSino Biologics and PNI collaborate to develop COVID-19 RNA vaccine

First U.K. frontline healthcare workers enrolled in the largest COVID-19 interventional trial

Kleo and Celularity collaborate to develop allogeneic NK-cell combination therapies

Health Canada gives clearance for phase II study of favipiravir as prophylactic against COVID-19

Cervello Therapeutics patents ROCK inhibitors

Merck & Co. discloses muscarinic M4 receptor PAMs

China NMPA gives clearance for phase II study of TJ-107/HyLeukin-7 in GBM

GPX2 as novel biomarker and target in bladder cancer

Phase I data published for Zika purified inactivated virus vaccine

ViiV Healthcare presents new antivirals for HIV infection

Esteve Pharmaceuticals synthesizes new analgesic drugs

New RET inhibitors presented by Medshine Discovery

Post-translational antibody modification triggers allergies

ACE correlates with antipsychotic treatment resistance in psychosis

CD8+/gp350-CAR+-T cells show efficacy in Epstein-Barr virus infection model

SV2A synaptic marker not altered by antipsychotic treatment in rats

FDA approves Kynmobi sublingual film to treat "off" episodes in Parkinson's disease

Final data show phase II study of ATL-1102 in DMD meets primary endpoint

Navidea reports second interim analysis from phase IIb study of Tc99m tilmanocept imaging in RA

Phase III trial of entinostat in HR-positive, HER-negative breast cancer misses primary endpoint

Vaxart selects lead COVID-19 vaccine candidate

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...